SC
REGN icon

Solstein Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Solstein Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.3K Sell
69
-2
-3% -$1.53K 0.02% 221
2025
Q4 		$54.8K Sell
71
-137
-66% -$93K 0.02% 203
2025
Q3 		$117K Sell
208
-40
-16% -$22.6K 0.03% 148
2025
Q2 		$130K Sell
248
-41
-14% -$22.9K 0.07% 134
2025
Q1 		$183K Sell
289
-10
-3% -$6.88K 0.11% 101
2024
Q4 		$213K Hold
299
– – 0.12% 91
2024
Q3 		$314K Hold
299
– – 0.17% 83
2024
Q2 		$314K Sell
299
-72
-19% -$69.8K 0.21% 78
2024
Q1 		$357K Hold
371
– – 0.25% 71
2023
Q4 		$326K Hold
371
– – 0.24% 72
2023
Q3 		$305K Sell
371
-12
-3% -$9.43K 0.26% 71
2023
Q2 		$275K Buy
383
+30
+8% +$23.1K 0.23% 72
2023
Q1 		$290K Buy
353
+89
+34% +$67.1K 0.25% 72
2022
Q4 		$190K Sell
264
-16
-6% -$11.8K 0.16% 93
2022
Q3 		$193K Buy
280
+5
+2% +$3.15K 0.17% 82
2022
Q2 		$163K Sell
275
-5
-2% -$3.25K 0.12% 112
2022
Q1 		$196K Sell
280
-738
-72% -$467K 0.13% 114
2021
Q4 		$643K Buy
1,018
+969
+1,978% +$596K 0.39% 71
2021
Q3 		$30K Hold
49
– – 0.02% 278
2021
Q2 		$27K Buy
49
+2
+4% +$1.01K 0.03% 269
2021
Q1 		$22K Buy
+47
New +$22.9K 0.03% 248
2020
Q4 		– Sell
-47
Closed -$26K – 182
2020
Q3 		$26K Hold
47
– – 0.06% 163
2020
Q2 		$29K Hold
47
– – 0.07% 146
2020
Q1 		$23K Hold
47
– – 0.09% 133
2019
Q4 		$18K Buy
+47
New +$15.8K 0.04% 204

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Solstein Capital's REGN Position: Q1 2026 in Review

Solstein Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 2.8% in Q1 2026, selling an estimated $1.53K and leaving 69 shares worth $53.3K. The position accounts for 0.02% of the portfolio, ranked #221.

Solstein Capital first reported a position in REGN in Q4 2019 and has held it in 25 quarters since. The position peaked at $643K in Q4 2021. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Solstein Capital held 69 shares of Regeneron Pharmaceuticals worth $53.3K as of Q1 2026.
  • Solstein Capital sold 2 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.53K.
  • Regeneron Pharmaceuticals made up 0.02% of Solstein Capital's portfolio in Q1 2026, its #221 holding.
  • Solstein Capital first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • Solstein Capital's Regeneron Pharmaceuticals position peaked at $643K in Q4 2021.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Solstein Capital's 13F filing for Q1 2026, filed 14 May 2026.